Evidence map›Paper›PMID 30742050›Full record

ArticleJournal of human hypertension2019

Stage 1 hypertension, but not elevated blood pressure, predicts 10-year fatal and non-fatal CVD events in healthy adults: the ATTICA Study.

Elena Critselis, Christina Chrysohoou, Natasa Kollia, Ekavi N Georgousopoulou, Dimitrios Tousoulis, Christos Pitsavos, Demosthenes B Panagiotakos, ATTICA Study group

Open access · bronzeAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of human hypertension, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. The heart in hypertension.Journal of human hypertension · 2021
    Article
  4. Article
  5. Should blood pressure ≥130/80 mm Hg be considered as a cardiovascular disease?Journal of clinical hypertension (Greenwich, Conn.) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Elena CritselisDepartment of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, 70 El. Venizelou Avenue, 176 71, Athens, Greece.
Christina ChrysohoouFirst Cardiology Clinic, School of Medicine, University of Athens, Athens, Greece.
Natasa KolliaDepartment of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, 70 El. Venizelou Avenue, 176 71, Athens, Greece.
Ekavi N GeorgousopoulouDepartment of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, 70 El. Venizelou Avenue, 176 71, Athens, Greece.
Dimitrios TousoulisFirst Cardiology Clinic, School of Medicine, University of Athens, Athens, Greece.
Christos PitsavosFirst Cardiology Clinic, School of Medicine, University of Athens, Athens, Greece.
Demosthenes B PanagiotakosDepartment of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, 70 El. Venizelou Avenue, 176 71, Athens, Greece. d.b.panagiotakos@usa.net.ORCID 0000-0001-8583-153X
ATTICA Study group
National and Kapodistrian University of Athens · GRUniversity of Canberra · AUHarokopio University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study evaluated the extent to which high normal blood pressure (HNBP), elevated BP, and Stage 1 hypertension predict 10-year incidence of cardiovascular disease (CVD). A population-based, prospective cohort study was conducted among 3042 randomly selected Greek adults, aged 18-89 years. Following 10-years follow-up (2002-2012), incidence of non-fatal and fatal CVD (ICD-10) was achieved in 2020 participants. The analytic sample (n = 1403) excluded hypertensive patients. At baseline, the prevalence rate of HNBP, elevated BP, and Stage 1 hypertension was 44.6% (n = 626), 29.0% (n = 408), and 15.5% (n = 218), respectively. During follow-up, the 10-year combined (fatal or non-fatal) CVD incidence rates in HNBP, elevated BP, and Stage 1 hypertensive individuals were 15.6% (n = 98), 12.0% (n = 49), and 22.5% (n = 49), respectively, as compared to 6.3% (n = 49) in normotensives (all p's < 0.0001). As compared to normotensives (and following the adjustment for known demographic, lifestyle and clinical confounding factors), HNBP participants had a 1.5-fold (Adjusted Hazard Ratio, Adj. HR: 1.49; 95% CI: 1.00-2.20) increased risk of 10-year CVD events. Similarly, Stage 1 hypertensive participants had an approximately twofold (Adj. HR: 1.90; 95% CI: 1.16-3.08) increased risk for 10-year CVD, particularly among males (Adj. HR: 2.03; 95% CI: 1.08-3.83). However, individuals with elevated BP did not exhibit a differential risk for developing 10-year CVD events (Adj. HR: 1.28; 95% CI: 0.82-2.02). Therefore, since HNBP and Stage 1 hypertension individuals exhibit a notable increased risk of 10-year fatal and non-fatal CVD, the implementation of targeted primary and secondary prevention interventions may deter both CVD and related adverse health outcomes.

Indexed as

Blood PressureAdolescentAdultAgedAged, 80 and overCardiovascular DiseasesCause of DeathFemaleGreeceHumansHypertensionIncidenceMaleMiddle AgedPrevalencePrognosis

Identifiers

PMID30742050
OpenAlexW2912950285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.